Navigation Links
Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACR Annual Meeting, Indivumed presented data which provide a sound scientific basis for a new drug test-platform to predict drug response in patients.

Tumor tissue-derived primary cell lines are currently the first choice for cancer drug testing. During their clonal selection and expansion, however, their gene and protein expression patterns change significantly, thereby losing many of their primary characteristics. Primary cell cultures are useful tools because they better reflect the molecular reality in tumors. A previous Indivumed study, however, showed that within 10 passages and after 10-12 weeks in culture, the molecular characteristics and target expression of these cells change significantly in >20% of cancer relevant genes, e.g. EGFR, HER2, VEGF, p53, CEA.

Gene expression data from short-term cultivated colorectal cancer primary cells show that in contrast to long-term cultivation (>1 month) primary cells cultivated for up to 72h do not change the molecular expression level of most cancer relevant genes. Some of the genes that play a role in cell to cell contact and tissue organization changed expression levels at various time points when compared to instantly frozen tumor tissue. These data provide a sound basis for Indivumed's new drug test-platform which allows molecular and functional analysis of molecular anti-cancer agents in a clinically meaningful system and, thus, a better prediction of clinical drug response.

Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington, D.C., Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of o ver 6000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's cancer research in primary cells and biomarkers as well as for the use of pharmaceutical and biopharma partners.

CONTACT: Hartmut Juhl, M.D., Ph.D., CEO of Indivumed GmbH, T:+49-40-413383-10, F: +49-40-413383-14, E: ; or KevinSullivan, Director, Marketing and Sales of Indivumed, Inc., T:+1-301-588-4650, E:

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... According to an ... groups has filed a discrimination claim against the U.S. Department of Health and Human ... Affordable Care Act (ACA) plans are breaking the clause in the law prohibiting the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... ... , ... Growth in medical payments per workers’ compensation claim in Louisiana slowed ... nonhospital care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... medical payments per claim with more than seven days of lost time continued to ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced ... Bridge Business Awards under the New Products and Services category for its innovative ... sample management software that helps labs organize data and track samples with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):